i2cPharm services (as a part of Cardiff Scintigraphics Ltd) is an established independent company with 29 years’ experience delivering evaluation, research and development programs involving a wide range of inhalation formulations and respiratory delivery devices, for global pharma, medical technology companies and emerging clients. i2cPharm supports its clients from early proof of concept laboratory innovations through to clinical studies of final product evaluation. Our dedicated early stage research and development services are available for a range of dosage forms, providing pathways for successful product development. Our bespoke clinical gamma scintigraphy imaging studies for both inhalation and gastrointestinal delivered dosage forms, can evaluate the in vivo deposition, residence, clearance and dispersion of drug products, in healthy volunteers and patients. Our integrated services provide a fast and effective route from innovation to clinic while reducing costs and time to market. i2cPharm also offers the Respitab® patented technology, a propellant-dispersible tablet as a cost-effective and innovative manufacturing platform which offers simplicity in the development and scale-up of new pMDI products, involving formulations of new drugs and combinations in propellants for the Next Generation pMDIs.
i2c Pharmaceutical Services / Cardiff Scintigraphics Ltd
Cardiff Medicentre
Heath Park
Cardiff, Wales CF14 4UJ
United Kingdom
+44 (0) 29 2075 7865
www.i2cpharm.co.uk
info@i2cpharm.co.uk
Inhalation Product Evaluation, Research and Development
Dedicated orally inhaled and nasal drug product analysis and testing services for pressurised metered dose inhalers, dry powder inhalers or nebulisers. Testing is performed by experienced scientists across the range of different inhalation dosage forms in accord with validated and robust methods. The testing is to support early stage formulation, to device screening, accelerated stability testing and through to batch release for in-house clinical scintigraphy trials. More Info
Scintigraphic Imaging
Gamma scintigraphy is an effective non-invasive imaging method for determining the bio-distribution of orally inhaled and nasal drug products (OINDPs) under physiological conditions, enabling key decision-making information during the clinical evaluation process. The i2cPharm/Scintigraphics team have 30 years of experience in scintigraphic validation and evaluation of OINDPs and in collaboration with Simbec-Orion offer fully integrated clinical scintigraphy services in healthy volunteers and patients. More Info
Respitab Propellant-Dispersible Tablet
The switch from hydrofluoroalkanes HFA 134a and 227 to lower carbon footprint propellants such as HFA 152a presents reformulation challenges for those involved in the manufacture of pressurised metered dose inhalers (pMDIs). Respitab is a propellant dispersible platform tablet technology designed to provide a simplified and cost-effective pathway to development of the Next Generation pMDIs. More Info
